Nuclear nano-morphology markers of histologically normal cells detect the “field effect” of breast cancer
- 266 Downloads
Accurate detection of breast malignancy from histologically normal cells (“field effect”) has significant clinical implications in a broad base of breast cancer management, such as high-risk lesion management, personalized risk assessment, breast tumor recurrence, and tumor margin management. More accurate and clinically applicable tools to detect markers characteristic of breast cancer “field effect” that are able to guide the clinical management are urgently needed. We have recently developed a novel optical microscope, spatial-domain low-coherence quantitative phase microscopy, which extracts the nanoscale structural characteristics of cell nuclei (i.e., nuclear nano-morphology markers), using standard histology slides. In this proof-of-concept study, we present the use of these highly sensitive nuclear nano-morphology markers to identify breast malignancy from histologically normal cells. We investigated the nano-morphology markers from 154 patients with a broad spectrum of breast pathology entities, including normal breast tissue, non-proliferative benign lesions, proliferative lesions (without and with atypia), “malignant-adjacent” normal tissue, and invasive carcinoma. Our results show that the nuclear nano-morphology markers of “malignant-adjacent” normal tissue can detect the presence of invasive breast carcinoma with high accuracy and do not reflect normal aging. Further, we found that a progressive change in nuclear nano-morphology markers that parallel breast cancer risk, suggesting its potential use for risk stratification. These novel nano-morphology markers that detect breast cancerous changes from nanoscale structural characteristics of histologically normal cells could potentially benefit the diagnosis, risk assessment, prognosis, prevention, and treatment of breast cancer.
KeywordsField effect Nanoscale structure Phase microscopy Nuclear nano-morphology markers
This study was supported by research grants from National Institute of Health (R21CA152935) and Wallace H. Coulter foundation. P. W. acknowledges the support from National Energy Technology Laboratory Research Participation Program sponsored by the U.S. Department of Energy and administered by the Oak Ridge Institute for Science and Education.
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12(22):6626–6636. doi: 10.1158/1078-0432.CCR-06-0467 PubMedCrossRefGoogle Scholar
- 16.Subramanian H, Pradhan P, Liu Y, Capoglu IR, Li X, Rogers JD, Heifetz A, Kunte D, Roy HK, Taflove A, Backman V (2008) Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells. Proc Natl Acad Sci USA 105(51):20118–20123. doi: 10.1073/pnas.0804723105 PubMedCrossRefGoogle Scholar
- 17.Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, Sturgis C, Hensing T, Ray D, Bogojevic A, Mohammed J, Chang JS, Backman V (2009) Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res 69(13):5357–5363. doi: 10.1158/0008-5472.CAN-08-3895 PubMedCrossRefGoogle Scholar
- 18.Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, Pass HI, Ray D, Rogers JD, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V (2010) Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res 70(20):7748–7754. doi: 10.1158/0008-5472.CAN-10-1686 PubMedCrossRefGoogle Scholar
- 26.Gonen M (2007) Analyzing receiver operating characteristic curves with SAS. SAS Institute, CaryGoogle Scholar
- 28.Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237. doi: 10.1056/NEJMoa044383 PubMedCrossRefGoogle Scholar